Drug Trial Radar · NCT02105467
Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
421
Actual
Start
Jun 5, 2014
Primary completion
Feb 26, 2015
Study completion Sep 6, 2015
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) in treatment-naive participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection. Participants were randomly assigned (3:1 ratio) to immediate treatment or deferred treatment (placebo control). The primary efficacy hypothesis was that the proportion of participants receiving combination therapy in the Immediate Treatment Arm who achieve sustained viral response at 12 weeks after the end of study treatment (SVR12) is superior to 73%.
Conditions
- Chronic Hepatitis C Virus
Interventions
Grazoprevir 100mg / Elbasvir 50 mg FDCDrug
Placebo to Grazoprevir / Elbasvir 50 mg FDCDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12)Time frame: Week 24 (12 weeks after the end of treatment)
- Percentage of Participants Experiencing at Least One Adverse EventTime frame: Up to Week 14 (14 days after the Blinded Treatment was completed)
- Percentage of Participants Discontinued From Study Treatment Because of an Adverse EventTime frame: Up to Week 12 (end of Blinded Treatment)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.